Peer-reviewed veterinary case report
IL-6 and thrombopoietin levels in dogs with carcinoma and high
By Cheney, Adrienne et al.·Published in Journal of veterinary internal medicine·2022·Department of Veterinary Clinical Sciences, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Interleukin-6 and thrombopoietin concentrations in dogs with carcinoma with and without thrombocytosis.
- Species:
- dog
Plain-English summary
A study looked at 116 dogs, including 63 with cancer (carcinoma) and 53 healthy dogs, to see if they had high levels of certain proteins related to blood platelets. They found that 19% of the dogs with cancer had high platelet counts (thrombocytosis), while none of the healthy dogs did. The dogs with cancer had significantly higher levels of thrombopoietin, a protein that helps produce platelets, compared to healthy dogs. However, the levels of another protein, interleukin-6, were similar in both groups. This suggests that thrombopoietin might play a role in how cancer affects platelet production in dogs.
People also search for: dog cancer symptoms · high platelet count in dogs · thrombocytosis in dogs · thrombopoietin levels in dogs
Abstract
BACKGROUND: Carcinoma-associated thrombocytosis involves tumor production of mediators such as interleukin-6 (IL-6) and thrombopoietin (TPO) that increase thrombopoiesis and may play a role in tumor evasion and metastasis. Carcinoma-associated thrombocytosis is described in people, but has not been described in dogs. HYPOTHESIS/OBJECTIVES: Evaluate the concentrations of IL-6 and TPO in dogs diagnosed with carcinoma with or without thrombocytosis. We hypothesized that IL-6 and TPO concentrations would be higher in dogs with carcinoma compared to healthy dogs, and that IL-6 and TPO concentrations would be higher in dogs with carcinoma and thrombocytosis when compared to dogs with carcinoma and normal platelet counts. ANIMALS: One-hundred sixteen dogs: 63 with carcinoma and 53 healthy control dogs. METHODS: Complete blood count was performed in all dogs, and they were stratified for sub-group analysis based on the presence or absence of thrombocytosis (platelet count > 500 103/µL). Serum TPO and IL-6 concentrations were measured by ELISA. Results of selected numeric variables were compared using Wilcoxon rank sum tests for pairwise comparisons. A value of P < .05 was considered significant. RESULTS: Twelve of the dogs with carcinoma (12/63, 19.0%) and none of the healthy control dogs (0%) had thrombocytosis. Thrombopoietin concentrations (median [range]) were significantly higher in dogs with carcinoma when compared to controls (87.42 pg/mL [0 to >600] vs 15.99 pg/mL [0 to >600], P < .001). Interleukin-6 concentrations (median [range]) were not different between dogs with carcinoma and healthy control dogs (9.70 pg/mL [0-181.53] vs 3.03 pg/mL [0-280.77], P = .15). In dogs with carcinoma, the TPO and IL-6 concentrations were not different between dogs with thrombocytosis and dogs with normal platelet count. CONCLUSIONS AND CLINICAL IMPORTANCE: Thrombopoietin concentrations were significantly higher in dogs with carcinoma, regardless of platelet count. Thrombopoietin is likely to be 1 of multiple factors that can impact platelet number, production, and consumption in dogs with carcinoma.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/34881459/